FUSION PROTEIN COMPRISING IFN-GAMMA AND ANTI-ERBB ANTIBODY FOR THE TREATMENT OF CANCERS
The present invention provides a fusion proteins comprising(a) a first stretch of consecutive amino acids, the sequence of which is the sequence of an anti-pl85her2/neu polypeptide or an anti-EGFR polypeptide;(b) a second stretch of consecutive amino acids, the sequence of which is the sequence of a polypeptide capable of binding at least one polypeptide other than pl85her2/neu or EGFR; and(c) a third stretch of consecutive amino acids, the sequence of which comprises the sequence of a biologically active portion of interferon-gamma (IFNy),wherein (b) is located at the carboxy-terminal end of (a), and (c) is located at the carboxy-terminal end of (b). The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administeringi) an anti-pl85her2/neu antibody or an anti-EGFR antibody and interferon-gamma (IFNy); orii) a fusion protein of the invention..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 22. Feb. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GREENE MARK [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-02-22, Last update posted on www.tib.eu: 2023-05-27, Last updated: 2023-06-06 |
|---|
| Patentnummer: |
EP4137519 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA016911334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA016911334 | ||
| 003 | DE-627 | ||
| 005 | 20230607091252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230607s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA016911334 | ||
| 035 | |a (EPA)EP4137519 | ||
| 035 | |a (EPA)52461974 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a GREENE MARK |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FUSION PROTEIN COMPRISING IFN-GAMMA AND ANTI-ERBB ANTIBODY FOR THE TREATMENT OF CANCERS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-02-22, Last update posted on www.tib.eu: 2023-05-27, Last updated: 2023-06-06 | ||
| 520 | |a The present invention provides a fusion proteins comprising(a) a first stretch of consecutive amino acids, the sequence of which is the sequence of an anti-pl85her2/neu polypeptide or an anti-EGFR polypeptide;(b) a second stretch of consecutive amino acids, the sequence of which is the sequence of a polypeptide capable of binding at least one polypeptide other than pl85her2/neu or EGFR; and(c) a third stretch of consecutive amino acids, the sequence of which comprises the sequence of a biologically active portion of interferon-gamma (IFNy),wherein (b) is located at the carboxy-terminal end of (a), and (c) is located at the carboxy-terminal end of (b). The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administeringi) an anti-pl85her2/neu antibody or an anti-EGFR antibody and interferon-gamma (IFNy); orii) a fusion protein of the invention. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG HONGTAO |4 aut | |
| 700 | 0 | |a TSUCHIYA HIROMICHI |4 aut | |
| 700 | 0 | |a NAGAI YASHUIRO |4 aut | |
| 700 | 0 | |a LAM LIAN |4 aut | |
| 700 | 0 | |a RUNKLE AARON |4 aut | |
| 700 | 0 | |a DREBIN JEFFREY |4 aut | |
| 700 | 0 | |a JI MEI QING |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 22. Feb. |
| 773 | 1 | 8 | |g year:2023 |g day:22 |g month:02 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/52461974/publication/EP4137519A1?q=EP4137519 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 22 |c 02 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 22 |c 02 | ||